RxDoctor Payments Data

Justin Goralnik, MD

Pulmonary Disease · Farmington, CTNPI 1134483951

Payments from drug & device makers

$3,640in general payments, 2019–2025

Across 64 payments — averaging $56.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Johnson & Johnson$1K
  • AstraZeneca$539
  • Covidien LP$336
  • GSK$98
  • Insmed, Inc.$29
  • plus $162 from 7 others

What the payments were for

  • Travel & lodging$1,61044%
  • Food & beverage$2,03156%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,640 in reported general payments places this provider in the 60th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$84,194
Medicare patients
293
Services billed
615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate23$301,137
Trelegy ElliptaFluticasone/Umeclidin/Vilanter219$200,347
Breo ElliptaFluticasone/Vilanterol309$168,178
XolairOmalizumab30$93,928
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr113$84,246
Dupixent PenDupilumab12$44,904
Spiriva RespimatTiotropium Bromide40$32,534
Spiriva HandihalerTiotropium Bromide26$17,376
SymbicortBudesonide/Formoterol Fumarate40$15,065
Combivent RespimatIpratropium/Albuterol Sulfate19$13,670
Arnuity ElliptaFluticasone Furoate25$9,176
Incruse ElliptaUmeclidinium Bromide15$8,105
Qvar RedihalerBeclomethasone Dipropionate27$7,454
DuleraMometasone/Formoterol17$7,213
Advair HfaFluticasone Propion/Salmeterol18$6,698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$98$470,051681 claims
AstraZenecaSymbicort$539$15,06540 claims
MerckDulera$26$7,21317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in Farmington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →